Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Pharmasset Reports Higher Than Expected Losses

February 8, 2011 6:21 am | News | Comments

Clinical-stage drugmaker Pharmasset Inc. reported a wider fiscal first-quarter loss Monday on higher research and development costs. The company lost $23.5 million, compared with a loss of $13.9 million the same quarter a year prior.

TOPICS:

GSK Adds Safety Restrictions to Avandia Label

February 8, 2011 6:18 am | by Matthew Perrone | News | Comments

GlaxoSmithKline PLC said it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.

TOPICS:

Danaher Acquiring Beckman Coulter for $6.8B

February 7, 2011 9:04 am | News | Comments

Beckman Coulter, Inc. announced that it has entered into a definitive merger agreement under which Danaher will acquire all of Beckman Coulter's outstanding common stock for $83.50 per share in cash.

TOPICS:
Advertisement

Bioterror Detection Assay

February 7, 2011 7:31 am | Product Releases | Comments

Abbott has introduced the PLEX-ID Biothreat Assay, which is designed to detect and distinguish 17 different biothreat pathogens. This assay enables rapid and accurate detection of potentially dangerous microorganisms.

TOPICS:

Full Stroke Diaphragms

February 7, 2011 7:27 am | Drug Discovery & Development | Product Releases | Comments

Wilden, a leader in air-operated double-diaphragm pump technology, will be introducing its new Full Stroke PTFE Diaphragms for use on all of its AODD pump lines at INTERPHEX 2011.

TOPICS:

Fluorescent Peptides Help Nerves Glow

February 7, 2011 7:19 am | News | Comments

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy.

TOPICS:

Research Connects 29 New Regions to IBD

February 7, 2011 7:17 am | News | Comments

An international team of researchers has made new links between 29 regions of the genome and ulcerative colitis. The new findings increase the total number of genome regions known to be associated with inflammatory bowel disease to 99.

TOPICS:

Acacia Wraps Up APD515 Trial

February 7, 2011 7:14 am | News | Comments

Acacia Pharma announces it has completed a Phase 1 clinical study of its product candidate APD515, an optimised oromucosal formulation of a currently marketed drug for the new use of treatment of dry mouth in advanced cancer patients.

TOPICS:
Advertisement

Regorafenib Receives Orphan Drug Status

February 7, 2011 7:12 am | News | Comments

Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors by the U.S. Food and Drug Administration.

TOPICS:

Pfizer Buying Ferrosan Consumer Health Division

February 7, 2011 7:02 am | News | Comments

Pfizer Inc. said it will expand its European business by acquiring Ferrosan's consumer health care business which includes vitamins and skincare products. The New York drugmaker did not disclose financial terms of the deal.

TOPICS:

Lilly CEO Pay Down 22%

February 7, 2011 7:00 am | by Tom Murphy | News | Comments

Eli Lilly and Co. Chairman and CEO John Lechleiter received compensation valued at $12.7 million last year, down 22 percent from 2009 largely due to a change in how the drugmaker handles equity awards.

TOPICS:

Crucell Loses On Vaccine Woes

February 7, 2011 6:57 am | News | Comments

Dutch biotechnology company Crucell NV said it had a net loss in the fourth quarter because of lower sales of its top selling vaccine, Quinvaxem, along with less demand for flu vaccines.

TOPICS:

Sanofi And Genzyme Board Discuss Deal

February 7, 2011 6:54 am | News | Comments

The boards of Sanofi-Aventis SA and Genzyme Corp. were scheduled to meet Sunday to discuss a deal between the two companies, but talks could continue throughout the week before a deal is finalized, according to a published report.

TOPICS:

Almac Opens North American Headquarters

February 7, 2011 6:30 am | News | Comments

Almac’s new 240,000 sq. ft. North American Headquarters, north of Philadelphia is part of the Almac Group’s integrated services solutions strategy. The facility delivers full-service, integrated solutions to pharmaceutical and biotech clients.

TOPICS:

Clovis Begins CP-4126 Trial Recruitment

February 4, 2011 7:32 am | News | Comments

Clavis Pharma, a Norwegian cancer drug development company, announces that its partner, Clovis Oncology, Inc., has recruited the first patient into a Phase 2 clinical study with CP-4126 (also known as CO-101).

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading